Immune Serum From Sabin Inactivated Poliovirus Vaccine Immunization Neutralizes Multiple Individual Wild and Vaccine-Derived Polioviruses. (13th April 2017)

• Record Type: Journal Article
• Authors: Sun, Mingbo; Li, Changgui; Xu, Wenbo; Liao, Guoyang; Li, Rongcheng; Zhou, Jian; Li, Yanping; Cai, Wei; Yan, Dongmei; Che, Yanchun; Ying, Zhifang; Wang, Jianfeng; Yang, Huijuan; Ma, Yan; Ma, Lei; Ji, Guang; Shi, Li; Jiang, Shude; Li, Qihan
• Is Part Of: Clinical infectious diseases. Volume 64:Number 10(2017)
• Page Start: 1317
• Page End: 1325
• Publication Date: 2017-04-13
• Subjects: Sabin-IPV -- immune serum -- cross neutralization -- polioviruses.; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/cix110
• Languages: English
• ISSNs: 1058-4838

Abstract

Summary: Our cross-neutralization assays suggest that the neutralizing antibody response induced by Sabin inactivated poliovirus vaccine is effective against all currently circulating wild poliovirus strains and most vaccine-derived poliovirus strains, with the possible exception of specific strains from chronic vaccine-derived infections. Abstract: Background: A Sabin strain–based inactivated poliomyelitis vaccine (Sabin-IPV) is the rational option for completely eradicating poliovirus transmission. The neutralizing capacity of Sabin-IPV immune serum to different strains of poliovirus is a key indicator of the clinical protective efficacy of this vaccine. Methods: Sera collected from 500 infants enrolled in a randomized, blinded, positive control, phase 2 clinical trial were randomly divided into 5 groups: Groups A, B, and C received high, medium, and low doses, respectively, of Sabin-IPV, while groups D and E received trivalent oral polio vaccine and Salk strain–based IPV, respectively, all on the same schedule. Immune sera were collected after the third dose of primary immunization, and tested in cross-neutralization assays against 19 poliovirus strains of all 3 types. Results: All immune sera from all 5 groups interacted with the 19 poliovirus strains with various titers and in a dose-dependent manner. One type 2 immunodeficiency-associated vaccine-derived poliovirus strain was not recognized by these immune sera. Conclusions: Sabin-IPV vaccine can induce protective antibodies against currently circulating and reference wild poliovirus strains and most vaccine-derived poliovirus strains, with rare exceptions. Clinical Trials Registration: NCT01056705